Physician profile
Preethi Ravichandran
NPI 1548403173
$781.92
in general payments reported to CMS, 2019-2025
15 companies · $87.11 in 2025
The $87.11 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.64 · 2021: $107 · 2022: $43.95 · 2023: $152 · 2024: $299 · 2025: $87.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.31 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $143.58 | 2021-2024 | |
| Novo Nordisk INC | $130.09 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $106.86 | 2024-2025 | Veozah |
| Intuitive Surgical, INC. | $82.05 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.06 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $57.72 | 2023 | Rexulti, Abilify Maintena |
| Arbor Pharmaceuticals, INC. | $30.66 | 2021 | |
| Avanir Pharmaceuticals, INC. | $28.58 | 2019 | |
| Intra-Sana Laboratories | $27.17 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Astrazeneca Pharmaceuticals Lp | $21.29 | 2024 | Brilinta |
| Halozyme INC | $20.77 | 2023 | |
| Aimmune Therapeutics, INC. | $18.73 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.52 | 2025 | |
| Gilead Sciences, INC. | $16.95 | 2023 | Veklury |
| Lucid Diagnostics INC. | $13.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preethi Ravichandran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.